Marina Biotech's platform and capabilities have unique potential for addressing the complexities of treating rare diseases. While our Familial Adenomatous Polyposis clinical program is advancing, we are also expanding our clinical pipeline to address myotonic dystrophy and Duchenne's muscular dystrophy.
Rare Disease Strategy
- Receive approval for and commercialize CEQ508 for FAP in the United States
- License CEQ508 outside the U.S.
- Achieve human proof-of-concept in myotonic dystrophy and Duchenne's muscular dystrophy.
- Develop additional rare disease programs through biotech and pharma partnering efforts